Celon Pharma SA

+ business areaBioPharma R&D+Services

+ company logotype
+ annual revenue

2019 - 102,247,000 PLN
2020 - 247,139,000 PLN
2021 - 194,592,000 PLN
2022 - 199,194,000 PLN
2023 - 216,566,000 PLN
2024 - 260,443,000 PLN

+ workforce (estimated if not reported)

2020 - 467
2021 - 488
2022 - 523
2023 - 515
2024 - 558

+ depreciation & amortization

2019 - -5,051,000 PLN
2020 - 70,904,000 PLN
2021 - 43,952,000 PLN
2022 - -8,314,000 PLN
2023 - -11,339,000 PLN
2024 - 52,236,000 PLN

Celon Pharma is a company specializing in the research and development of innovative drugs for the treatment of cancer, Alzheimer’s disease, and other central nervous system disorders. The company’s pipeline includes several drug candidates, including small molecules and biologics, in various stages of development. Celon Pharma is also focused on developing drug delivery systems to improve the effectiveness and safety of their therapies. With a strong focus on innovation and quality, Celon Pharma is committed to bringing new therapies to patients in need, while also expanding its global presence through partnerships and collaborations with leading pharmaceutical companies.